Drug Trial Radar · NCT01363752
A Study Looking at Kidney Function in Kidney Transplant Recipients Who Are Taking Anti-rejection Medication Including Tacrolimus and With or Without Sirolimus.
Last checked: Nov 20, 2026Latest source record: Oct 31, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
853
Actual
Start
Mar 8, 2011
Primary completion
Sep 18, 2013
Study completion Sep 18, 2013
Sponsor
- Lead sponsor
- Astellas Pharma IncAstellas (ALPMY)
- Sponsor type
- Industry
- First posted
- Jun 2, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the effect of two anti-rejection therapy regimens on kidney function in kidney transplant recipients.
Conditions
- Kidney Transplantation
Interventions
AdvagrafDrug
oral
Mycophenolate MofetilDrug
oral
SirolimusDrug
oral
CorticosteroidsDrug
i.v. and oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Glomerular Filtration Rate (GFR) estimated by iohexol clearance at Week 52 post kidney transplantationTime frame: up to 1 year
Locations
58 sites in 17 countries. Site status is shown where the registry gives one.
5042
New Lambton, Australia
5043
Perth, Australia
1141
Innsbruck, Austria
1142
Linz, Austria
1140
Vienna, Austria
3240
Minsk, Belarus
1241
Leuven, Belgium
1240
Liège, Belgium
Site 1441
Brno, Czechia
1440
Ostrava - Poruba, Czechia
1752
Amiens, France
1740
Brest, France
1742
Clermont-Ferrand, France
1746
Créteil, France
1750
Dijon, France
1741
Le Kremilin Bicetre Cedex, France
1749
Paris, France
1751
Toulouse, France
1748
Tours, France
1745
Vandœuvre-lès-Nancy, France
1541
Bochum, Germany
1542
Erlangen, Germany
1543
Essen, Germany
1544
Frankfurt, Germany
1545
Hannoversch Münden, Germany
1540
Hanover, Germany
1546
Heidelberg, Germany
1547
Kiel, Germany
1548
Leipzig, Germany
1549
München, Germany
1550
Münster, Germany
5441
Hong Kong, Hong Kong
1940
Budapest, Hungary
2144
Palermo, Italy
2143
Roma, Italy
2140
Siena, Italy
2440
Maastricht, Netherlands
2643
Katowice, Poland
2640
Lodz, Poland
2641
Poznan, Poland
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.